Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPC | P11150 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29477529 | 1.00 | LIPC (0.33) | LIPCLIPGDYRK2DYRK1A | |
| SCHEMBL32689233 | 1.00 | LIPC (0.33) | LIPCLIPGDYRK2DYRK1A | |
| SCHEMBL30514966 | 0.92 | LIPC (0.32) | LIPCLIPG | |
| SCHEMBL25335607 | 0.92 | LIPC (0.32) | LIPCLIPG | |
| SCHEMBL25335611 | 0.92 | LIPC (0.32) | LIPCLIPG | |
| SCHEMBL29477779 | 0.91 | LIPC (0.32) | LIPCLIPG | |
| SCHEMBL32689303 | 0.91 | LIPC (0.32) | LIPCLIPG | |
| SCHEMBL25955541 | 0.91 | LIPC (0.32) | LIPCLIPG | |
| SCHEMBL25922186 | 0.91 | LIPC (0.33) | LIPCLIPGDYRK2DYRK1A | |
| SCHEMBL25922177 | 0.91 | LIPC (0.33) | LIPCLIPGDYRK2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | LIPC 815/4885LIPG 2618/4885DYRK2 4351/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | LIPC 815/4885LIPG 2618/4885DYRK2 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.